Using the immune system to stop ovarian cancer

August 16, 2023 9:00 am

The search for preventions and cures has turned inward—focusing on the immune system to stop ovarian cancer.

Professor Paul Hertzog’s research group at Hudson Institute of Medical Research has been working to expand on their discovery of a naturally occurring … Read more

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Read more

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

June 3, 2023 7:02 am

Key takeaways:

  • Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
  • The relative contribution of durvalumab requires further study.

 

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more

SWOG investigators report results from DART clinical trial of immunotherapy combination for rare gynecologic cancers

April 18, 2023 10:20 am

Reviewed by Emily Henderson, B.Sc

Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting Read more

Chemotherapy-resistant ovarian cancer cells protect their neighbors, shows study

March 3, 2023 10:10 am

by University of Pittsburgh

Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12, 2023 10:08 am

by Ryan Scott

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)

Read more

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

September 26, 2022 9:49 am

by Megan Hollasch

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal Read more

Phase 1 Success of Targeting MUC16 in Patients With Recurrent Ovarian Cancer

September 14, 2022 1:11 pm

by Jordyn Sava

In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.

Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more

TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors

September 10, 2022 10:50 am

by Victoria Johnson

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including

Read more

Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors

September 6, 2022 1:48 pm

CCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20, 2022 12:09 pm

by Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the Read more

Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer

April 13, 2022 2:12 pm

by Conor Killmurray

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

The use of dual immune checkpoint

Read more

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11, 2022 9:46 am

by Jonah Fieldman

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results, according to data

Read more

Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer

March 20, 2022 9:55 am

by Hayley Virgil

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses

Read more

Novel metabolic mechanisms contribute to how ovarian cancer evades immune attack, research finds

March 16, 2022 9:43 am

by Emily Henderson, B.Sc.

High-grade serous carcinoma is the most aggressive form of ovarian cancer and accounts for the majority of advanced-stage cases. The poor outcomes associated with the disease underscore the need for more effective treatments. A research team … Read more

‘Drug factory’ implants eliminate ovarian, colorectal cancer in mice

March 2, 2022 11:45 am

by Jade Boyd

Rice immunotherapy treatment could begin human clinical trials this year

HOUSTON – (March 2, 2022) – Rice University bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days

Read more

The secret hideouts of ovarian cancer revealed

February 11, 2022 9:53 am

Every year, roughly 550 women develop ovarian cancer in Finland. Ovarian cancer is difficult to treat and it is commonly fatal, with 320 women dying of ovarian cancer annually in Finland.

Cancer can only develop and progress when the tumour … Read more

Ludwig Lausanne team devises a method to selectively grow tumor-targeting T cells for cancer therapy

November 15, 2021 10:02 am

NOVEMBER 15, 2021, NEW YORK – A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens—small fragments of randomly mutated proteins that are typically unique to a … Read more